Form 4: Abbott Laboratories Director Michael F. Roman Acquires Additional Stock Equivalent Units

Sentiment:

Insider Transaction Report 1 July 2025 5:24 PM

Abbott Laboratories Director Michael F. Roman acquired 271 stock equivalent units on June 30, 2025, increasing his beneficial ownership to 5,250 units.

Summary

Michael F. Roman, a Director of Abbott Laboratories (ABT), acquired 271 stock equivalent units on June 30, 2025.
These units were credited as director fees, valued at $136.01 per unit.
Stock equivalent units are paid in cash, generally at age 65 or upon retirement from the board, and earn the same return as if the fees were invested in Abbott shares.
Following this transaction, Michael F. Roman beneficially owns 5,250 stock equivalent units.
The total balance of 5,250 units includes those acquired through a dividend reinvestment feature.

Sentiment

Score: 7

Explanation: The filing indicates a routine insider transaction where a director acquired stock equivalent units as part of their compensation. This is generally viewed positively as it aligns director interests with shareholders, but it's not a significant market-moving event on its own.

Positives

Acquisition of stock equivalent units by a director aligns their interests with shareholders, indicating confidence in the company's future performance.
The mechanism of crediting director fees as stock equivalent units encourages long-term commitment and performance-based compensation.

Future Outlook

Industry Context

This is a routine insider transaction disclosure. It reflects a common practice of compensating directors with equity-linked instruments to align their interests with shareholders, a standard corporate governance practice across various industries, particularly in large, established companies like those in the healthcare sector.

Comparison to Industry Standards

The practice of compensating directors with stock equivalent units is a common corporate governance standard, aligning director incentives with long-term shareholder value, similar to practices at peer companies in the pharmaceutical and medical device industry such as Johnson & Johnson (JNJ) or Medtronic (MDT).
The acquisition of units as part of director fees, rather than open market purchases, is a standard method for non-employee directors to build equity ownership in the company.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Director Compensation Structure	Director fees are credited to a stock equivalent unit account, which are paid in cash generally at age 65 or upon retirement from the board. These units earn the same return as if the fees were invested in Abbott shares.	NA	This structure aligns director incentives with long-term shareholder value by linking compensation to the company's stock performance.
Power of Attorney Grant	Michael F. Roman granted power of attorney to specific individuals (Elizabeth C. Cushman, Jessica H. Paik, and Aaron N. Rice) to prepare, sign, and file SEC forms and documents on his behalf, including those required under Rule 144 and Section 16(a).	06/13/2025	Streamlines the process for timely and accurate SEC filings for the director, ensuring compliance with regulatory requirements.

Stakeholder Impact

Shareholders: The acquisition of stock equivalent units by a director aligns their interests with shareholders, potentially signaling confidence in the company's future and promoting long-term value creation.

Key Dates

Date	Description
06/13/2025	Date of Power of Attorney granted by Michael F. Roman.
06/30/2025	Date of transaction where Michael F. Roman acquired 271 stock equivalent units.
07/01/2025	Date the Form 4 was signed by Michael F. Roman's attorney-in-fact.

Recommendation

hold

Keywords

Abbott Laboratories, ABT, Michael F. Roman, Form 4, SEC Filing, Insider Transaction, Director Compensation, Stock Equivalent Units, Beneficial Ownership, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.